[{"id":"b742dbe7-45f3-484c-87c3-e57f6a13cfbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04914351","created_at":"2024-03-13T20:35:51.807Z","updated_at":"2024-07-02T16:35:15.082Z","phase":"Phase 1","brief_title":"HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours","source_id_and_acronym":"NCT04914351","lead_sponsor":"Shanghai HyaMab Biotech Co.,Ltd.","biomarkers":" HLA-E • KLRC1","pipe":"","alterations":" ","tags":["HLA-E • KLRC1"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/03/2022","start_date":" 05/03/2022","primary_txt":" Primary completion: 11/27/2023","primary_completion_date":" 11/27/2023","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2024-03-13"},{"id":"792e293a-0452-40c2-8e37-6f70f357fc89","acronym":"","url":"https://clinicaltrials.gov/study/NCT03895996","created_at":"2022-04-11T13:52:38.588Z","updated_at":"2024-07-02T16:35:59.237Z","phase":"Phase 1/2","brief_title":"Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes","source_id_and_acronym":"NCT03895996","lead_sponsor":"Avotres Inc.","biomarkers":" HLA-E","pipe":"","alterations":" ","tags":["HLA-E"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/20/2019","start_date":" 06/20/2019","primary_txt":" Primary completion: 05/17/2022","primary_completion_date":" 05/17/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-12-12"}]